Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 20:00:55 13/03/2026 GMT			5-day change	1st Jan Change
115.61 ^USD	-0.26%		-0.16%	+9.83%

03-12	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03-10	Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says	MT

Press Releases

03-03	Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion	PR
03-02	Merck - KEYTRUDA Plus Paclitaxel with or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival versus Paclitaxel with or without Bevacizumab in Patients	AQ
03-02	Merck - WELIREG plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients with Advanced Renal Cell Carcinoma	AQ
03-02	Merck - KEYTRUDA plus Padcev Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery	AQ
03-02	Merck - KEYTRUDA plus WELIREG Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients with Earlier-Stage Renal Cell Carcinoma	AQ
02-28	KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)	BU
02-28	WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)	BU
02-27	KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer	BU
02-27	KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery	BU
02-25	FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis	BU
02-25	Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026	BU
02-24	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge	PR
02-24	Merck to Participate in the TD Cowen 46th Annual Health Care Conference	BU
02-24	Nykode Therapeutics Announces New Interim Data from the VB-C-03 Trial Showing Encouraging Anti-Tumor Activity and Tolerability of Abi-suva (VB10.16)	AQ
02-23	Merck Evolves Human Health Operating Structure to Support Portfolio Execution	BU
02-19	Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons	BU
02-18	Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine	BU
02-17	Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications	AQ
02-12	Merck - KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel +/- Bevacizumab, Approved for Certain Adults with PD-L1+ Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment	AQ
02-12	Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	AQ
02-12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium	BU
02-11	KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment	BU
02-05	Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants	AQ
02-03	Merck : remembers Dr. William Foege, Architect of Early Mectizan® Delivery Efforts - Merck.com	PU
02-03	Merck : Icon 4Q25 Merck Earnings Presentation	PU